ATE551073T1 - Markierte hgf-bindende peptide für bildgebung - Google Patents

Markierte hgf-bindende peptide für bildgebung

Info

Publication number
ATE551073T1
ATE551073T1 AT08750628T AT08750628T ATE551073T1 AT E551073 T1 ATE551073 T1 AT E551073T1 AT 08750628 T AT08750628 T AT 08750628T AT 08750628 T AT08750628 T AT 08750628T AT E551073 T1 ATE551073 T1 AT E551073T1
Authority
AT
Austria
Prior art keywords
imaging
binding peptides
labelled
monitoring
vivo
Prior art date
Application number
AT08750628T
Other languages
English (en)
Inventor
Edvin Johannesen
Alan Cuthbertson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709441A external-priority patent/GB0709441D0/en
Priority claimed from GB0715682A external-priority patent/GB0715682D0/en
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Application granted granted Critical
Publication of ATE551073T1 publication Critical patent/ATE551073T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4842Monitoring progression or stage of a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Solid State Image Pick-Up Elements (AREA)
AT08750628T 2007-05-16 2008-05-16 Markierte hgf-bindende peptide für bildgebung ATE551073T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0709441A GB0709441D0 (en) 2007-05-16 2007-05-16 Peptide imaging agents
GB0715682A GB0715682D0 (en) 2007-08-13 2007-08-13 Peptide imaging agents
PCT/GB2008/001696 WO2008139207A2 (en) 2007-05-16 2008-05-16 Labelled hgf binding peptides for imaging

Publications (1)

Publication Number Publication Date
ATE551073T1 true ATE551073T1 (de) 2012-04-15

Family

ID=39743846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08750628T ATE551073T1 (de) 2007-05-16 2008-05-16 Markierte hgf-bindende peptide für bildgebung

Country Status (17)

Country Link
US (1) US8529874B2 (de)
EP (1) EP2146749B1 (de)
JP (1) JP2010526859A (de)
KR (2) KR20150017387A (de)
CN (1) CN101848734B (de)
AT (1) ATE551073T1 (de)
AU (1) AU2008249821B2 (de)
BR (1) BRPI0811210B1 (de)
CA (1) CA2685553C (de)
ES (1) ES2385066T3 (de)
IL (1) IL201778A0 (de)
MX (1) MX2009012386A (de)
NZ (1) NZ581160A (de)
PL (1) PL2146749T3 (de)
RU (2) RU2475266C2 (de)
WO (1) WO2008139207A2 (de)
ZA (1) ZA200908016B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581161A (en) * 2007-05-16 2012-06-29 Ge Healthcare As Optical imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
CN103052690A (zh) * 2010-06-29 2013-04-17 通用电气医疗集团股份有限公司 染料组合物和染料合成
GB201010878D0 (en) 2010-06-29 2010-08-11 Ge Healthcare As Dye compositiion and dye syntheses
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012048063A2 (en) * 2010-10-06 2012-04-12 Emd Millipore Corporation Cyanine compounds, conjugates and method of use
CN103687627A (zh) 2011-03-01 2014-03-26 通用电气健康护理有限公司 作为pet示踪剂的放射性标记的奥曲肽酸类似物
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
DE102011118029A1 (de) * 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2014152718A1 (en) * 2013-03-15 2014-09-25 Arizona Board Of Regents, For And On Behalf Of Arizona State University Saccharide conjugates
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN105111773B (zh) * 2015-08-19 2017-06-27 大连理工大学 一类氨基菁类荧光染料及其制备方法和应用
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CN112129736B (zh) * 2020-09-22 2022-08-02 四川大学华西医院 粘蛋白和循环肿瘤细胞的均相可视化/荧光poct检测方法
CN117425705A (zh) * 2021-06-07 2024-01-19 索高视觉有限公司 用于近红外荧光验证的稳定液体体模
TW202404643A (zh) 2022-04-20 2024-02-01 大陸商同宜醫藥(蘇州)有限公司 化合物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517152T1 (de) 2002-05-10 2011-08-15 Univ Carnegie Mellon Chirale indole als zwischenprodukte und daraus hergestellte cyaninfluoreszenzfarbstoffe mit funktionellen gruppen
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004075032A2 (en) * 2003-02-19 2004-09-02 Sicel Technologies Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
US20050214859A1 (en) * 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
ATE522580T1 (de) * 2003-10-31 2011-09-15 Ge Healthcare Ltd Cyaninfarbstoffe als markieragenzien
JP2007510643A (ja) 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
NO20035682D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
WO2006078914A1 (en) * 2005-01-21 2006-07-27 Washington University In St. Louis Compounds having rd targeting motifs
GB0502277D0 (en) 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
NO20053354D0 (no) 2005-07-11 2005-07-11 Amersham Health As Optical imaging contrast agent.

Also Published As

Publication number Publication date
WO2008139207A2 (en) 2008-11-20
BRPI0811210B1 (pt) 2021-11-09
US8529874B2 (en) 2013-09-10
RU2475266C2 (ru) 2013-02-20
EP2146749B1 (de) 2012-03-28
ES2385066T3 (es) 2012-07-17
AU2008249821A1 (en) 2008-11-20
KR20150017387A (ko) 2015-02-16
PL2146749T3 (pl) 2012-09-28
RU2009140475A (ru) 2011-06-27
CA2685553C (en) 2017-03-28
AU2008249821B2 (en) 2013-08-22
BRPI0811210A2 (pt) 2014-11-11
JP2010526859A (ja) 2010-08-05
MX2009012386A (es) 2009-12-03
IL201778A0 (en) 2010-06-16
CN101848734B (zh) 2013-08-28
WO2008139207A3 (en) 2009-02-26
RU2009140478A (ru) 2011-06-27
KR101578225B1 (ko) 2015-12-17
ZA200908016B (en) 2012-04-25
CN101848734A (zh) 2010-09-29
KR20100016543A (ko) 2010-02-12
RU2473361C2 (ru) 2013-01-27
NZ581160A (en) 2012-05-25
CA2685553A1 (en) 2008-11-20
EP2146749A2 (de) 2010-01-27
US20100150843A1 (en) 2010-06-17
RU2473361C9 (ru) 2013-06-20

Similar Documents

Publication Publication Date Title
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
GB0718967D0 (en) Peptide imaging agents
BR112012033406A2 (pt) anticorpo para diagnóstico e/ou prognóstico de câncer
WO2011015602A3 (en) Lung cancer biomarkers
WO2013096845A3 (en) Methods for diagnosis of lung cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
UA106771C2 (uk) Моноклональні антитіла до прогастрину та їх використання
NZ598194A (en) Anti-cmet antibody and its use for the detection and the diagnosis of cancer
WO2008104803A3 (en) Proteins
UA113712C2 (xx) Антитіло до fap і способи його застосування
MX2011006422A (es) Autoanticuerpos humanos anti-alfa-sinucleina.
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
GEP201706737B (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
EA201591020A1 (ru) Человеческие анти-тау антитела
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
WO2010132370A3 (en) Soluble tlt-1 for the treatment and diagnosis of sepsis
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
MX2011006773A (es) Biomarcador.
WO2009016231A3 (en) Compositions and methods for detecting histamine related disorders